8-K: Maze Therapeutics Reports Q1 2026 Financials, Positive Trial Data

Maze Therapeutics announced positive topline data from its Phase 2 HORIZON trial for MZE829 in AMKD, alongside strong financial results and an extended cash runway into 2029.

Summary

• Maze Therapeutics reported positive topline data from the Phase 2 HORIZON trial of MZE829 for APOL1-Mediated Kidney Disease (AMKD), showing a 35.6% mean reduction in proteinuria.
• The company plans to initiate a pivotal trial for MZE829 in moderate AMKD patients without diabetes in the first half of 2027.
• Phase 2 trials for MZE782 in Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) are on track to start in 2026, with PKU data expected in 2027.
• Maze Therapeutics ended the first quarter of 2026 with $362.9 million in cash, cash equivalents, and marketable securities.
• The company raised approximately $150 million in a registered offering in April 2026 and received a $20 million milestone payment, extending its cash runway into 2029.
• First quarter 2026 net loss was $24.2 million, or $0.45 per share, an improvement from $32.8 million, or $1.15 per share, in the first quarter of 2025.
• Research and development expenses increased to $34.1 million from $27.6 million, driven by clinical trial costs and personnel expenses.
• General and administrative expenses rose to $12.4 million from $7.8 million, primarily due to personnel and professional service costs.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report due to strong clinical data, significant financing, and an extended cash runway, indicating substantial progress and de-risking of key programs.

Positives

• Positive topline data from Phase 2 HORIZON trial of MZE829 in AMKD, demonstrating a clinically meaningful mean reduction in proteinuria of 35.6% at week 12.
• 50% of patients in the HORIZON trial achieved a greater than 30% reduction in uACR.
• Significant proteinuria reduction observed in specific patient subgroups: 61.8% in severe FSGS and 48.6% in AMKD without diabetes.
• No serious adverse events or severe treatment-related adverse events were observed in the HORIZON trial.
• Strong balance sheet with $362.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
• Raised approximately $150 million in a registered offering in April 2026.
• Received a $20 million milestone payment from Shionogi & Co., Ltd. in April 2026.
• Expected cash runway extended into 2029.
• License revenue of $20.0 million recognized in Q1 2026 due to a milestone achievement.
• Reduced net loss to $24.2 million ($0.45/share) in Q1 2026 from $32.8 million ($1.15/share) in Q1 2025.

Negatives

• R&D expenses increased by $6.5 million to $34.1 million in Q1 2026 compared to Q1 2025, driven by clinical trial and personnel costs.
• G&A expenses increased by $4.6 million to $12.4 million in Q1 2026 compared to Q1 2025, due to personnel and professional services costs.
• In patients with AMKD and diabetes in the HORIZON trial, only 2 out of 5 evaluable patients achieved at least a 30% reduction in uACR.
• Net loss of $24.2 million reported for Q1 2026.

Risks

• The company's ability to advance MZE829, MZE782, and other therapeutic candidates through clinical trials and obtain regulatory approval.
• The timing and results of preclinical studies and clinical trials may differ from expectations.
• The company's ability to fund its development activities and achieve its development goals.
• Risks related to the protection of intellectual property.
• General business and economic conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises.
• Potential for future clinical trials to reveal safety or efficacy issues not observed in earlier studies.
• Regulatory feedback may impact the initiation timeline for the pivotal MZE829 trial.

Future Outlook

Maze Therapeutics expects its current cash, cash equivalents, and marketable securities, combined with proceeds from a recent offering and a milestone payment, to fund operations into 2029. The company plans to initiate Phase 2 trials for MZE782 in PKU and CKD in 2026, with PKU data expected in 2027. Additional data from the MZE829 HORIZON trial is anticipated in late 2026 or early 2027, with a pivotal trial for MZE829 planned for the first half of 2027.

Management Comments

• "We continue to execute across our clinical pipeline in 2026, and with positive topline data reported from our Phase 2 HORIZON trial of MZE829 in broad AMKD in the first quarter, we are more confident than ever in our potential to harness the power of genetics to transform the lives of patients."
• "Looking ahead to the rest of the year, we remain on track to initiate a Phase 2 trial of MZE782 in PKU around the middle of this year with topline data expected in 2027, and an additional Phase 2 study is expected to initiate in CKD in the second half of this year."
• "We also look forward to reporting additional results from the HORIZON study in late 2026 or early 2027, and to advancing MZE829 into a pivotal trial in moderate AMKD patients without diabetes, including those with FSGS."
• "With a strong balance sheet and expected cash runway into 2029, we continue to focus on clinical execution and pivotal study preparation."

Industry Context

StockSavvy.ai notes that Maze Therapeutics' progress with MZE829 in AMKD aligns with the broader industry trend of developing precision medicines targeting genetically defined patient populations. The positive Phase 2 results and planned pivotal trial advancement position the company to address a significant unmet need in kidney disease, a complex therapeutic area where many large pharmaceutical companies have faced challenges.

Comparison to Industry Standards

• The reported 35.6% mean reduction in proteinuria for MZE829 in AMKD patients is a strong signal for a Phase 2 trial, especially given the genetic basis of the disease. Comparable trials in CKD often aim for reductions in the 20-30% range, making Maze's result noteworthy.
• The company's ability to secure $150 million in a registered offering and a $20 million milestone payment demonstrates investor confidence in its pipeline, a positive indicator in the current biopharmaceutical funding environment.
• The projected cash runway into 2029 is robust for a clinical-stage company, allowing for sustained development and de-risking of its lead programs, which is a key factor for institutional investors.

Stakeholder Impact

• Shareholders: Positive impact from strong clinical data, successful capital raise, and extended cash runway, potentially increasing future value.
• Patients: Potential for new treatment options for AMKD, PKU, and CKD with MZE829 and MZE782.
• Employees: Continued employment and potential growth opportunities due to company progress and funding.
• Creditors: Improved financial stability due to increased cash reserves and extended runway.

Next Steps

• Initiate a pivotal trial for MZE829 in moderate AMKD patients without diabetes in the first half of 2027.
• Initiate Phase 2 proof-of-concept trials for MZE782 in PKU by mid-2026.
• Initiate Phase 2 proof-of-concept trial for MZE782 in CKD in the second half of 2026.
• Report additional results from the HORIZON study in late 2026 or early 2027.
• Report topline data from the MZE782 Phase 2 trial in PKU in 2027.

Key Dates

Recommendation

The combination of compelling Phase 2 data for MZE829, a clear path to a pivotal trial, progress on MZE782, a robust cash position with an extended runway into 2029, and successful capital raising events presents a highly favorable risk-reward profile. The company is well-positioned to achieve significant value inflection points.

Keywords

Maze Therapeutics, MZE829, AMKD, kidney disease, MZE782, PKU, CKD, biopharmaceutical